Related references
Note: Only part of the references are listed.Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy
Ajai Chari et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Cost of decentralizedCART-cell production in an academic nonprofit setting
Tao Ran et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment
Jort J. van der Schans et al.
FRONTIERS IN ONCOLOGY (2020)
Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity
Anat Globerson Levin et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1/2 Evolve Study (NCT03430011)
Julia Piasecki et al.
BLOOD (2020)
Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma
Mehmet K. Samur et al.
BLOOD (2020)
Orvacabtagene Autoleucel (orva-cel; JCARH125): A Fully Human BCMA-Targeted Second-Generation CAR T Cell Product Characterized By a Predominant Central Memory Phenotype with High in Vitro and In Vivo Proliferative Potential and Sustained In Vivo Persistence
Lucrezia Colonna et al.
BLOOD (2020)
Health State Utility Valuation in Patients with Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy, Idecabtagene Vicleucel (ide-cel, bb2121): Results from the Karmma Trial
Michel Delforge et al.
BLOOD (2020)
Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells (CT053) in Relapsed/Refractory Multiple Myeloma
Siguo Hao et al.
BLOOD (2020)
Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin's Lymphoma (NHL)
Arushi Khurana et al.
BLOOD (2020)
Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study
Yi Lin et al.
BLOOD (2020)
Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis
Jesus G. Berdeja et al.
BLOOD (2020)
Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes
Melissa Alsina et al.
BLOOD (2020)
Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies
Caitlin L. Costello et al.
BLOOD (2020)
Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Alfred L. Garfall et al.
BLOOD (2020)
Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy
Noemie Leblay et al.
BLOOD (2020)
Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma
Sham Mailankody et al.
BLOOD (2020)
Chimeric antigen receptor -T cells with cytokine neutralizing capacity
Adrian H. J. Tan et al.
BLOOD ADVANCES (2020)
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Ujjawal H. Gandhi et al.
LEUKEMIA (2019)
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
Adam D. Cohen et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma
Cesar Sommer et al.
MOLECULAR THERAPY (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
leExploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
Jie Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
Zhiling Yan et al.
LANCET HAEMATOLOGY (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
Rosalie M. Sterner et al.
BLOOD (2019)
Sequential CD19-and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study
Lingzhi Yan et al.
BLOOD (2019)
Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
Deepu Madduri et al.
BLOOD (2019)
Long-Term Follow-up of a Phase 1, Firstin-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Bai-Yan Wang et al.
BLOOD (2019)
A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial
Chenggong Li et al.
BLOOD (2019)
Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+T Cell Central Memory Cell Subset
Enrique Zudaire et al.
BLOOD (2019)
Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma
Chunrui Li et al.
BLOOD (2019)
Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma
Andrew J. Cowan et al.
BLOOD (2019)
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma (vol 3, e120505, 2018)
Alfred L. Garfall et al.
JCI INSIGHT (2019)
T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma
Alfred L. Garfall et al.
BLOOD ADVANCES (2019)
Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies
Adam D. Cohen et al.
BLOOD ADVANCES (2019)
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
Kevin M. Friedman et al.
HUMAN GENE THERAPY (2018)
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Bianca D. Santomasso et al.
CANCER DISCOVERY (2018)
Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma
De-Xiu Bu et al.
Oncotarget (2018)
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Wan-Hong Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial
Sham Mailankody et al.
BLOOD (2018)
Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma
Xiuli Wang et al.
CLINICAL CANCER RESEARCH (2018)
A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
Esther Drent et al.
MOLECULAR THERAPY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
Oladapo O. Yeku et al.
SCIENTIFIC REPORTS (2017)
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Jakub Krejcik et al.
CLINICAL CANCER RESEARCH (2017)
T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy
David J. Chung et al.
CANCER IMMUNOLOGY RESEARCH (2016)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
Yu-Tzu Tai et al.
BLOOD (2016)
Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution
Laurens E. Franssen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Design of chimeric antigen receptors with integrated controllable transient functions
Alexandre Juillerat et al.
SCIENTIFIC REPORTS (2016)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Robert O. Carpenter et al.
CLINICAL CANCER RESEARCH (2013)
A human memory T cell subset with stem cell-like properties
Luca Gattinoni et al.
NATURE MEDICINE (2011)
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Antonio Di Stasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
BCMA is essential for the survival of long-lived bone marrow plasma cells
BP O'Connor et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR zeta/CD28 receptor
J Maher et al.
NATURE BIOTECHNOLOGY (2002)
Share Paper
